Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy

Objectives Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide,...

Full description

Bibliographic Details
Main Authors: Barnaby Hunt, Hongye Ren, Sasha Berry, Samuel Joseph Paul Malkin, Stephen Bain
Format: Article
Language:English
Published: BMJ Publishing Group 2023-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/9/e070473.full